

MSN Laboratories introduces affordable JAK Inhibitors in India

13 October 2025 | News

Bringing affordable bioequivalent medications to alleviate the suffering of Indian patients



Hyderabad-based MSN Laboratories has announced that it is the first to launch the revolutionary JAK inhibitor molecules Tofacitinib (Tofadoz) and Upadacitinib (Upadoz) in India.

This launch significantly enhances the accessibility and affordability of advanced treatments for patients suffering from various autoimmune diseases, including Rheumatoid Arthritis, Psoriatic Arthritis, Ulcerative Colitis, Crohn's Disease, and Atopic Dermatitis. Both molecules are also approved by the US FDA.

MSN Laboratories is committed to providing affordable medicines, having previously launched close to 50 first-time molecules in India. The company holds the leading position in Active Pharmaceutical Ingredient (API) US DMF filings.

"The introduction of Upadoz reflects our commitment to bringing affordable bioequivalent medications to alleviate the suffering of Indian patients," said Dr M.S.N. Reddy, Founder and CMD, MSN Group.

Bharat Reddy, Executive Director, MSN Group, added: "Autoimmune diseases are a growing public health issue, and the cost of treatment is substantial. This launch will make treatment more accessible to Indian patients."